OSTEOPORE LIMITED — Capital/Financing Update 2023

Apr 13, 2023

==> picture [145 x 59] intentionally omitted <==

ASX RELEASE | OSTEOPORE LIMITED

OSTEOPORE INCREASES PRESENCE IN SINGAPORE DENTAL & ORAL MAXILLOFACIAL MARKET

Highlights:

• Distribution agreement signed with Majeton Pte Ltd, to market and sell Osteopore’s dental and oral maxillofacial products in Singapore .

• The agreement aims to improve Osteopore’s presence in the dental and oral maxillofacial market.

• With an initial three-year term, Majeton will immediately begin engaging with doctors and hospitals, both government and private.

• Osteopore aims to continue expanding its network to enable greater accessibility to a wider range of products.

14 April 2023: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”), an Australian and Singapore based global leader in the manufacture of innovative regenerative implants that empower natural tissue regeneration, is pleased to announce it has signed an exclusive Distribution Agreement with Majeton Pte Ltd (Majeton) to promote and sell Osteopore’s dental and oral maxillofacial products in Singapore.

According to the latest statistics published by the Ministry of Health[1] , Singapore has 899 private dental clinics and 248 public dental clinics spread across the country. Leveraging the network of Majeton, Osteopore dental products will now be made readily available across Singapore. In addition, Majeton will also approach public and private hospitals to promote and sell Osteopore’s oral maxillofacial range of products. This distribution partnership is especially meaningful as it enables Osteopore to leverage the sales network of Majeton to drive adoption of its dental and oral maxillofacial products.

Majeton (a wholly owned subsidiary of Essex Bio-Technology), is a sales, marketing and distribution company of therapeutics, medical devices and nutraceuticals for the region of South East Asia. The company embraces innovation to provide a portfolio of first-in-class and best-in-class products with the aim to deliver solutions to commercial and clinical unmet needs, covering a wide range of therapeutic areas.

1 https://www.moh.gov.sg/resources-statistics/singapore-health-facts/health-facilities

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com

==> picture [145 x 59] intentionally omitted <==

Under the terms of the three-year, exclusive agreement, Majeton will market and sell Osteopore’s innovative products for use in guided bone regeneration, immediate implant loading, and socket preservation. In unique situations, Osteopore may also make customised regenerative implants available for various oral maxillofacial reconstruction. Osteopore will now work closely with Majeton to train its sales representatives to facilitate ongoing promotion across dental clinics and hospitals in Singapore.

Osteopore Executive Chairman, Mark Leong said:

“The dental business is a significant opportunity for us globally. This is a step taken in the right direction of growing our dental presence in the region. We are delighted to work with Majeton, which has strong commercial presence and recognises the benefit that our technology brings to our patients.”

“We are excited to have established a strategic partnership with Osteopore in Singapore,” said Malcolm Ngiam, Executive Director of Majeton. “Osteopore recognises our strong commercial presence in Singapore and both organisations will work hand-in-hand to bring to market innovative products supported by advanced 3D printing technology for improved clinical outcomes for dental patients."

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman Osteopore Limited +65 9011 7009 Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Limited is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. Osteopore's patent-protected scaffolds are made from proprietary polymer formulations, that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing postsurgery complications commonly associated with permanent bone implants.

About Majeton

Majeton (a wholly owned subsidiary of Essex Bio-Technology), is a sales, marketing and distribution company of therapeutics, medical devices and nutraceuticals for the region of South East Asia. The company embraces innovation to provide a portfolio of first-in-class and best-in-class products with the aim to deliver solutions to commercial and clinical unmet needs, covering a wide range of therapeutic areas.

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com

==> picture [145 x 59] intentionally omitted <==

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com